Holders — by stockHoldings — by fund
SR One Capital Management, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001910264
$1.04B
disclosed book value
15
positions
28.4%
largest position share
Positions, as of 2026-06-30
top 15 of 15 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | MANEVeradermics, Inc. | 2.4M | $295.3M | 28.4% |
| 2 | ZBIOZenas BioPharma, Inc | 5.0M | $127.9M | 12.3% |
| 3 | CRISPR Therapeutics AG | 2.0M | $111.2M | 10.7% |
| 4 | AVLNAvalyn Pharma, Inc | 3.3M | $108.9M | 10.5% |
| 5 | DSGNDesign Therapeutics, Inc. | 6.5M | $94.4M | 9.1% |
| 6 | ODTXOdyssey Therapeutics, Inc. | 3.8M | $71.0M | 6.8% |
| 7 | ALMSAlumis Inc. | 2.0M | $55.2M | 5.3% |
| 8 | ORICORIC Pharmaceuticals, Inc. | 4.6M | $50.0M | 4.8% |
| 9 | MLYSMineralys Therapeutics Inc. | 1.6M | $42.2M | 4.1% |
| 10 | SPRYARS Pharmaceuticals, Inc. | 4.0M | $32.1M | 3.1% |
| 11 | MOBIMobia Medical, Inc | 2.0M | $26.6M | 2.6% |
| 12 | NKTXNkarta, Inc. | 3.3M | $9.4M | 0.9% |
| 13 | Oculis Holding AG | 641,022 | $8.9M | 0.9% |
| 14 | RAREUltragenyx Pharmaceutical Inc. | 137,753 | $4.6M | 0.4% |
| 15 | enGene Holdings Inc. | 747,750 | $1.3M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.